KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Royalty Pharma's Amortization - Intangibles history spans 4 years, with the latest figure at $5.7 million for Q1 2022.

  • For Q1 2022, Amortization - Intangibles changed 0.02% year-over-year to $5.7 million; the TTM value through Dec 2022 reached $5.7 million, down 75.34%, while the annual FY2022 figure was $5.7 million, 75.34% down from the prior year.
  • Amortization - Intangibles for Q1 2022 was $5.7 million at Royalty Pharma, down from $5.8 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $5.8 million in Q4 2019 and bottomed at $5.7 million in Q1 2022.
  • The 4-year median for Amortization - Intangibles is $5.8 million (2019), against an average of $5.8 million.
  • The largest annual shift saw Amortization - Intangibles changed 0.0% in 2020 before it decreased 1.08% in 2021.
  • A 4-year view of Amortization - Intangibles shows it stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then dropped by 2.17% to $5.7 million in 2022.
  • Per Business Quant, the three most recent readings for RPRX's Amortization - Intangibles are $5.7 million (Q1 2022), $5.8 million (Q4 2021), and $5.8 million (Q3 2021).